Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Completed
Pfizer
Phase 3
2008-12-01
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase
alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase
(Cerezyme®) enzyme replacement therapy.
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
Completed
Protalix
Phase 3
2008-12-01
This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase
alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase
(Cerezyme®) enzyme replacement therapy.
A Study in Type 1 Gaucher Patients to Evaluate the Pharmacokinetics, Safety and Pharmacodynamics of AT2101
Terminated
Amicus Therapeutics
Phase 1
2009-04-01
This is an open-label study designed to assess if AT2101 is safe in patients with Gaucher
disease and how AT2101 gets through the body after it is taken by mouth. The study is being
offered to adult patients with type 1 Gaucher disease who are currently receiving a stable
dose of enzyme replacement therapy (ERT) with imiglucerase. During the study, subjects will
not be receiving ERT (up to 35 days).
The study consists of a screening period (~14 days), a treatment period (12 days) and a
follow-up period (7 days after last dose). At two points in the study, subjects will be
housed in an in-patient treatment facility for 3 days/2 nights to accommodate all necessary
blood draws.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
